Back to today’s briefing

Story perspectives

Wegovy and Zepbound: Weight Loss Race Heats Up

1/18/2025

50 11

Summary

Story summary

Novo Nordisk's Wegovy has made waves in the STEP UP trial, boasting an impressive average weight loss of 20.7% over 72 weeks among 1,407 participants. In contrast, those on a lower dose lost 17.5%, while the placebo group saw just 2.4%. Yet, Eli Lilly's Zepbound edges ahead with a slightly higher 20.9% weight loss.

1 of 1

Story summary

Novo Nordisk's Wegovy has made waves in the STEP UP trial, boasting an impressive average weight loss of 20.7% over 72 weeks among 1,407 participants. In contrast, those on a lower dose lost 17.5%, while the placebo group saw just 2.4%. Yet, Eli Lilly's Zepbound edges ahead with a slightly higher 20.9% weight loss.